LCI - Lannett Co Stock Price, News & Analysis

$25.55 1.00 (4.07 %)
(As of 11/24/2017 02:04 AM ET)
Previous Close$24.55
Today's Range$24.50 - $25.65
52-Week Range$14.90 - $27.90
Volume862,900 shs
Average Volume790,959 shs
Market Capitalization$962.40 million
P/E Ratio9.13
Dividend YieldN/A
Beta2.73

About Lannett Co (NYSE:LCI)

Lannett Co logoLannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.


Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:LCI
CUSIP51601210

Debt

Debt-to-Equity Ratio1.44%
Current Ratio2.52%
Quick Ratio1.90%

Price-To-Earnings

Trailing P/E Ratio9.13
Forward P/E Ratio8.55
P/E Growth2.05

Sales & Book Value

Annual Sales$633.34 million
Price / Sales1.52
Cash Flow$4.56 per share
Price / Cash5.60
Book Value$15.30 per share
Price / Book1.67

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS$1.12
Net Income$-580,000.00
Net Margins6.67%
Return on Equity18.23%
Return on Assets6.16%

Miscellaneous

Employees1,126
Outstanding Shares37,670,000

Frequently Asked Questions for Lannett Co (NYSE:LCI)

What is Lannett Co's stock symbol?

Lannett Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."

How were Lannett Co's earnings last quarter?

Lannett Co Inc (NYSE:LCI) announced its earnings results on Monday, November, 6th. The company reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.52 by $0.08. The business earned $155 million during the quarter, compared to analysts' expectations of $153.62 million. Lannett Co had a return on equity of 18.23% and a net margin of 6.67%. The business's revenue was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.77 earnings per share. View Lannett Co's Earnings History.

When will Lannett Co make its next earnings announcement?

Lannett Co is scheduled to release their next quarterly earnings announcement on Tuesday, January, 30th 2018. View Earnings Estimates for Lannett Co.

Where is Lannett Co's stock going? Where will Lannett Co's stock price be in 2017?

5 brokers have issued 1-year target prices for Lannett Co's shares. Their predictions range from $18.00 to $27.00. On average, they expect Lannett Co's stock price to reach $21.50 in the next twelve months. View Analyst Ratings for Lannett Co.

Who are some of Lannett Co's key competitors?

Who are Lannett Co's key executives?

Lannett Co's management team includes the folowing people:

  • Jeffrey Farber, Chairman of the Board (Age 56)
  • Arthur P. Bedrosian J.D., Chief Executive Officer, Director (Age 71)
  • Martin P. Galvan CPA, Chief Financial Officer, Vice President - Finance, Treasurer (Age 65)
  • John Kozlowski, Corporate Chief Operating Officer (Age 45)
  • Robert Ehlinger, Vice President - Logistics, Chief Information Officer (Age 58)
  • Samuel H. Israel, Vice President, General Counsel, Chief Legal Officer (Age 55)
  • Kevin R. Smith, Vice President - Sales and Marketing (Age 57)
  • John M. Abt, Vice President - Quality (Age 52)
  • David Drabik, Lead Independent Director (Age 49)
  • Patrick G. LePore, Independent Director (Age 62)

Who owns Lannett Co stock?

Lannett Co's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Thompson Siegel & Walmsley LLC (2.71%), Dimensional Fund Advisors LP (2.22%), Russell Investments Group Ltd. (1.80%), Heartland Advisors Inc. (1.34%), Muhlenkamp & Co. Inc. (1.21%) and Bank of New York Mellon Corp (0.96%). Company insiders that own Lannett Co stock include Arthur P Bedrosian, David A Drabik, David Farber, G Michael Landis, James M Maher, Kevin Smith, Martin P Galvan and Robert Ehlinger. View Institutional Ownership Trends for Lannett Co.

Who sold Lannett Co stock? Who is selling Lannett Co stock?

Lannett Co's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Heartland Advisors Inc., Prudential Financial Inc., Ameriprise Financial Inc., State Board of Administration of Florida Retirement System, Muhlenkamp & Co. Inc., Pinnacle Associates Ltd. and Bank of New York Mellon Corp. Company insiders that have sold Lannett Co company stock in the last year include Arthur P Bedrosian and David Farber. View Insider Buying and Selling for Lannett Co.

Who bought Lannett Co stock? Who is buying Lannett Co stock?

Lannett Co's stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Thompson Siegel & Walmsley LLC, Russell Investments Group Ltd., Nationwide Fund Advisors, Cubist Systematic Strategies LLC, Schwab Charles Investment Management Inc., Convergence Investment Partners LLC and First Trust Advisors LP. Company insiders that have bought Lannett Co stock in the last two years include Arthur P Bedrosian, David A Drabik, Kevin Smith and Martin P Galvan. View Insider Buying and Selling for Lannett Co.

How do I buy Lannett Co stock?

Shares of Lannett Co can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lannett Co's stock price today?

One share of Lannett Co stock can currently be purchased for approximately $25.55.

How big of a company is Lannett Co?

Lannett Co has a market capitalization of $962.40 million and generates $633.34 million in revenue each year. The company earns $-580,000.00 in net income (profit) each year or $1.12 on an earnings per share basis. Lannett Co employs 1,126 workers across the globe.

How can I contact Lannett Co?

Lannett Co's mailing address is 9000 State Rd, PHILADELPHIA, PA 19136-1615, United States. The company can be reached via phone at +1-215-3339000.


MarketBeat Community Rating for Lannett Co (LCI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  216 (Vote Underperform)
Total Votes:  503
MarketBeat's community ratings are surveys of what our community members think about Lannett Co and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Lannett Co (NYSE:LCI)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 3 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $21.50 (15.85% downside)

Consensus Price Target History for Lannett Co (NYSE:LCI)

Price Target History for Lannett Co (NYSE:LCI)

Analysts' Ratings History for Lannett Co (NYSE:LCI)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017BMO Capital MarketsBoost Price TargetMarket Perform$20.00 -> $22.00N/AView Rating Details
8/23/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldHighView Rating Details
8/22/2017Roth CapitalSet Price TargetBuy$27.00HighView Rating Details
8/14/2017Deutsche Bank AGLower Price TargetHold$23.00 -> $19.00MediumView Rating Details
5/3/2017Robert W. BairdReiterated RatingOutperform$18.00MediumView Rating Details
8/24/2016Raymond James Financial, Inc.Boost Price TargetOutperform$31.00 -> $43.00N/AView Rating Details
3/25/2016Susquehanna Bancshares IncLower Price Target$37.00 -> $30.00N/AView Rating Details
3/25/2016Craig HallumLower Price TargetBuy$35.00N/AView Rating Details
3/24/2016Canaccord GenuityDowngradeBuy -> Sell$28.00 -> $18.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Lannett Co (NYSE:LCI)

Earnings by Quarter for Lannett Co (NYSE:LCI)

Earnings History by Quarter for Lannett Co (NYSE LCI)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/30/2018N/AView Earnings Details
11/6/2017Q1 2018$0.52$0.60$153.62 million$155.00 millionViewN/AView Earnings Details
8/23/2017Q4 2017$0.40$0.40$139.01 million$139.10 millionViewN/AView Earnings Details
5/2/2017Q3 2017$0.87$0.77$170.28 million$165.72 millionViewListenView Earnings Details
2/1/2017Q217$0.84$0.92$169.04 million$171.00 millionViewListenView Earnings Details
11/3/2016Q117$0.71$0.77$166.72 million$161.60 millionViewN/AView Earnings Details
8/23/2016Q416$0.59$0.73$161.55 million$168.90 millionViewListenView Earnings Details
5/3/2016Q316$0.63$0.75$160.49 million$163.70 millionViewN/AView Earnings Details
2/3/2016Q216$0.94$0.95$141.62 million$127.06 millionViewN/AView Earnings Details
11/4/2015Q116$0.89$0.99$103.90 million$106.40 millionViewN/AView Earnings Details
8/25/2015Q415$0.86$0.91$97.21 million$99.28 millionViewListenView Earnings Details
5/6/2015Q315$0.94$0.97$101.10 million$99.40 millionViewN/AView Earnings Details
2/4/2015Q215$1.06$1.21$102.95 million$114.80 millionViewN/AView Earnings Details
11/3/2014Q115$0.79$0.94$91.40 million$93.40 millionViewN/AView Earnings Details
8/27/2014Q414$0.63$0.64$79.50 million$80.60 millionViewN/AView Earnings Details
5/7/2014Q314$0.60$0.63$84.50 million$80.00 millionViewN/AView Earnings Details
2/6/2014Q214$0.39$0.46$62.21 million$67.30 millionViewN/AView Earnings Details
11/7/2013Q114$0.13$0.22$41.14 million$45.82 millionViewN/AView Earnings Details
9/10/2013Q4 2013$0.07$0.12$37.89 million$40.20 millionViewN/AView Earnings Details
5/8/2013Q3 2013$0.13$0.14$35.14 million$39.00 millionViewN/AView Earnings Details
2/7/2013Q2 2013$0.05$0.10$33.53 million$36.60 millionViewN/AView Earnings Details
11/8/2012Q113$0.05$0.07$33.76 million$35.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lannett Co (NYSE:LCI)
2017 EPS Consensus Estimate: $3.28
2018 EPS Consensus Estimate: $2.90
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.65$0.73$0.69
Q2 20173$0.80$0.91$0.86
Q3 20173$0.82$0.93$0.89
Q4 20173$0.72$0.93$0.84
Q1 20182$0.52$0.68$0.60
Q2 20182$0.68$0.76$0.72
Q3 20182$0.72$0.80$0.76
Q4 20182$0.73$0.90$0.82
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lannett Co (NYSE:LCI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Lannett Co (NYSE LCI)

Insider Ownership Percentage: 15.04%
Institutional Ownership Percentage: 96.83%
Insider Trades by Quarter for Lannett Co (NYSE:LCI)
Institutional Ownership by Quarter for Lannett Co (NYSE:LCI)

Insider Trades by Quarter for Lannett Co (NYSE LCI)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/8/2017Arthur P BedrosianCEOSell7,422$25.20$187,034.40View SEC Filing  
11/8/2017David FarberMajor ShareholderSell10,000$25.03$250,300.00View SEC Filing  
2/6/2017Arthur P BedrosianCEOBuy10,000$20.00$200,000.00View SEC Filing  
12/2/2016David FarberMajor ShareholderSell3,800$25.00$95,000.00View SEC Filing  
9/15/2016G. Michael LandisInsiderSell4,334$32.30$139,988.20View SEC Filing  
9/1/2016James M MaherDirectorSell1,478$33.91$50,118.98View SEC Filing  
8/31/2016G. Michael LandisInsiderSell6,786$33.41$226,720.26View SEC Filing  
6/23/2016Robert EhlingerVPSell37,141$25.06$930,753.46View SEC Filing  
6/20/2016Robert EhlingerVPSell62,859$25.40$1,596,618.60View SEC Filing  
3/1/2016Robert EhlingerVPSell69,247$25.41$1,759,566.27View SEC Filing  
2/5/2016Arthur P BedrosianCEOBuy4,500$24.91$112,095.00View SEC Filing  
2/5/2016David A DrabikDirectorBuy1,277$24.74$31,592.98View SEC Filing  
2/5/2016Kevin SmithVPBuy1,500$24.75$37,125.00View SEC Filing  
2/5/2016Martin P GalvanCFOBuy3,000$24.65$73,950.00View SEC Filing  
9/15/2015Arthur P BedrosianCEOSell5,000$55.64$278,200.00View SEC Filing  
9/8/2015John AbtVPBuy1,000$54.77$54,770.00View SEC Filing  
8/17/2015Arthur P BedrosianCEOSell5,000$52.81$264,050.00View SEC Filing  
7/15/2015Arthur P BedrosianCEOSell5,000$61.92$309,600.00View SEC Filing  
6/15/2015Arthur P BedrosianCEOSell5,000$56.31$281,550.00View SEC Filing  
5/15/2015Arthur P BedrosianCEOSell5,000$53.27$266,350.00View SEC Filing  
4/15/2015Arthur P BedrosianCEOSell5,000$69.43$347,150.00View SEC Filing  
3/16/2015Arthur P BedrosianCEOSell5,000$65.23$326,150.00View SEC Filing  
3/16/2015William SchreckCOOSell134,635$64.99$8,749,928.65View SEC Filing  
3/6/2015William SchreckCOOSell50,000$63.35$3,167,500.00View SEC Filing  
2/18/2015David A DrabikDirectorSell12,500$61.55$769,375.00View SEC Filing  
2/17/2015Arthur P BedrosianCEOSell5,000$59.89$299,450.00View SEC Filing  
2/17/2015G. Michael LandisInsiderSell11,500$58.60$673,900.00View SEC Filing  
2/13/2015Jeffrey FarberDirectorSell35,000$58.18$2,036,300.00View SEC Filing  
2/11/2015Kevin SmithVPSell109,436$56.51$6,184,228.36View SEC Filing  
2/9/2015David FarberMajor ShareholderSell2,500$55.00$137,500.00View SEC Filing  
2/9/2015Kevin SmithVPSell53,534$55.36$2,963,642.24View SEC Filing  
2/6/2015G. Michael LandisInsiderSell12,049$52.93$637,753.57View SEC Filing  
1/26/2015David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  
1/15/2015Arthur P BedrosianCEOSell5,000$43.50$217,500.00View SEC Filing  
12/15/2014Arthur P BedrosianCEOSell5,000$43.81$219,050.00View SEC Filing  
12/10/2014Martin P GalvanCFOBuy1,000$42.40$42,400.00View SEC Filing  
12/8/2014Ernest SaboVPSell6,000$48.03$288,180.00View SEC Filing  
10/27/2014David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  
9/16/2014Arthur P BedrosianCEOSell5,000$40.05$200,250.00View SEC Filing  
8/18/2014David FarberMajor ShareholderSell5,000$41.30$206,500.00View SEC Filing  
7/15/2014Arthur P BedrosianCEOSell5,000$47.19$235,950.00View SEC Filing  
6/23/2014David FarberMajor ShareholderSell7,500$50.00$375,000.00View SEC Filing  
6/16/2014Arthur P BedrosianCEOSell5,000$46.96$234,800.00View SEC Filing  
6/16/2014David FarberMajor ShareholderSell10,000$43.53$435,300.00View SEC Filing  
6/16/2014Paul TaveiraDirectorSell1,000$46.94$46,940.00View SEC Filing  
3/17/2014William SchreckCOOSell16,600$43.85$727,910.00View SEC Filing  
3/12/2014William SchreckCOOSell55,563$43.31$2,406,433.53View SEC Filing  
2/20/2014Kevin SmithVPSell64,665$45.11$2,917,038.15View SEC Filing  
2/13/2014Kevin SmithVPSell20,000$40.48$809,600.00View SEC Filing  
12/13/2013Arthur BedrosianCEOBuy5,000$27.85$139,250.00View SEC Filing  
12/13/2013Martin GalvanCFOBuy3,000$26.90$80,700.00View SEC Filing  
5/14/2013Kevin SmithVPSell24,984$11.86$296,310.24View SEC Filing  
5/13/2013Kevin SmithVPSell41,929$11.80$494,762.20View SEC Filing  
5/10/2013Ernest SaboVPSell15,000$11.29$169,350.00View SEC Filing  
3/14/2013Paul TaveiraDirectorBuy1,000$9.73$9,730.00View SEC Filing  
2/13/2013Martin P GalvanCFOBuy4,000$6.88$27,520.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Lannett Co (NYSE LCI)

Source:
DateHeadline
Aralez Pharmaceuticals (ARLZ) versus Lannett Co (LCI) Head to Head ComparisonAralez Pharmaceuticals (ARLZ) versus Lannett Co (LCI) Head to Head Comparison
www.americanbankingnews.com - November 22 at 11:10 PM
$186.29 Million in Sales Expected for Lannett Co Inc (LCI) This Quarter$186.29 Million in Sales Expected for Lannett Co Inc (LCI) This Quarter
www.americanbankingnews.com - November 22 at 7:04 AM
Noteworthy Tuesday Option Activity: LCI, OFG, LAMRNoteworthy Tuesday Option Activity: LCI, OFG, LAMR
www.thestreet.com - November 22 at 1:46 AM
Lannett Has Emerged From Its Disastrous Merger And Struggling PeersLannett Has Emerged From Its Disastrous Merger And Struggling Peers
seekingalpha.com - November 22 at 1:46 AM
Is It Time To Buy Lannett Company Inc (LCI) Based Off Its PE Ratio?Is It Time To Buy Lannett Company Inc (LCI) Based Off Its PE Ratio?
finance.yahoo.com - November 21 at 2:42 AM
Contrasting Pacira Pharmaceuticals (PCRX) and Lannett Co (LCI)Contrasting Pacira Pharmaceuticals (PCRX) and Lannett Co (LCI)
www.americanbankingnews.com - November 18 at 5:12 AM
Lannett Co Inc (LCI) Price Target Raised to $22.00 at BMO Capital MarketsLannett Co Inc (LCI) Price Target Raised to $22.00 at BMO Capital Markets
www.americanbankingnews.com - November 13 at 10:50 AM
Lannett To Present At The Jefferies 2017 London Healthcare Conference On November 15Lannett To Present At The Jefferies 2017 London Healthcare Conference On November 15
finance.yahoo.com - November 11 at 4:03 PM
Scott+Scott, Attorneys at Law, LLP is Investigating Derivative Claims on Behalf of Shareholders of Lannett Company, Inc. (LCI)Scott+Scott, Attorneys at Law, LLP is Investigating Derivative Claims on Behalf of Shareholders of Lannett Company, Inc. (LCI)
finance.yahoo.com - November 11 at 4:03 PM
Insider Selling: Lannett Co Inc (LCI) CEO Sells 7,422 Shares of StockInsider Selling: Lannett Co Inc (LCI) CEO Sells 7,422 Shares of Stock
www.americanbankingnews.com - November 9 at 7:29 PM
Lannett Co Inc (LCI) Major Shareholder Sells $250,300.00 in StockLannett Co Inc (LCI) Major Shareholder Sells $250,300.00 in Stock
www.americanbankingnews.com - November 9 at 7:28 PM
Lannett Joins Elite Club Of Stocks With RS Ratings Over 90Lannett Joins Elite Club Of Stocks With RS Ratings Over 90
finance.yahoo.com - November 8 at 1:35 PM
Lannetts (LCI) CEO Arthur Bedrosian on Q1 2018 Results - Earnings Call TranscriptLannett's (LCI) CEO Arthur Bedrosian on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 6:26 AM
Lannett Reports Solid Fiscal 2018 First-Quarter Financial Results, Significantly Increases Fiscal 2018 GuidanceLannett Reports Solid Fiscal 2018 First-Quarter Financial Results, Significantly Increases Fiscal 2018 Guidance
finance.yahoo.com - November 7 at 6:26 AM
Lannett beats Street 1Q forecastsLannett beats Street 1Q forecasts
finance.yahoo.com - November 7 at 6:26 AM
Edited Transcript of LCI earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of LCI earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 6:26 AM
Lannett Co Inc (LCI) Issues Quarterly  Earnings Results, Beats Estimates By $0.08 EPSLannett Co Inc (LCI) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - November 6 at 9:52 PM
Lannett (LCI) Comments On Amended Civil Complaint; Intends to Vigorously Defend the ClaimsLannett (LCI) Comments On Amended Civil Complaint; Intends to Vigorously Defend the Claims
www.streetinsider.com - November 2 at 5:13 AM
Lannett takes issue with multi-state civil complaint over generic drug price fixingLannett takes issue with multi-state civil complaint over generic drug price fixing
seekingalpha.com - November 2 at 5:12 AM
Lannett Comments On Amended Civil ComplaintLannett Comments On Amended Civil Complaint
finance.yahoo.com - November 2 at 5:12 AM
Lannett Co Inc (LCI) Given Consensus Recommendation of "Hold" by AnalystsLannett Co Inc (LCI) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 1 at 5:32 PM
Celgene and Lannett settle Thalomid patent infringement dispute, Lannett OK to market generic equivalent August 1,2019Celgene and Lannett settle Thalomid patent infringement dispute, Lannett OK to market generic equivalent August 1,2019
seekingalpha.com - November 1 at 5:17 AM
EXAS Ups Outlook, NEOS Rejects PDLI Offer, Not Much To Smile About For CRY - NasdaqEXAS Ups Outlook, NEOS Rejects PDLI Offer, Not Much To Smile About For CRY - Nasdaq
www.nasdaq.com - October 31 at 5:34 AM
Lannett And Celgene Enter Into Settlement And License Agreement Related To Thalomid®Lannett And Celgene Enter Into Settlement And License Agreement Related To Thalomid®
finance.yahoo.com - October 31 at 12:32 AM
Lannett works out a deal with CelgeneLannett works out a deal with Celgene
finance.yahoo.com - October 31 at 12:32 AM
ETFs with exposure to Lannett Co., Inc. : October 30, 2017ETFs with exposure to Lannett Co., Inc. : October 30, 2017
finance.yahoo.com - October 31 at 12:32 AM
$0.52 Earnings Per Share Expected for Lannett Co Inc (LCI) This Quarter$0.52 Earnings Per Share Expected for Lannett Co Inc (LCI) This Quarter
www.americanbankingnews.com - October 30 at 9:20 PM
Lannett Co Inc (LCI) Scheduled to Post Earnings on MondayLannett Co Inc (LCI) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 1:50 PM
Head to Head Contrast: Lannett Co (LCI) vs. Its CompetitorsHead to Head Contrast: Lannett Co (LCI) vs. Its Competitors
www.americanbankingnews.com - October 28 at 1:30 AM
Lannett To Report Fiscal 2018 First-Quarter Financial Results, Host Conference Call On Monday, November 6Lannett To Report Fiscal 2018 First-Quarter Financial Results, Host Conference Call On Monday, November 6
finance.yahoo.com - October 26 at 5:09 PM
Lannett Co Inc (LCI) Upgraded to Hold at Zacks Investment ResearchLannett Co Inc (LCI) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 24 at 11:56 PM
ETFs with exposure to Lannett Co., Inc. : October 20, 2017ETFs with exposure to Lannett Co., Inc. : October 20, 2017
finance.yahoo.com - October 21 at 5:56 AM
Head to Head Review: Lannett Co (LCI) versus Akorn (AKRX)Head to Head Review: Lannett Co (LCI) versus Akorn (AKRX)
www.americanbankingnews.com - October 20 at 12:32 AM
CoLucid Pharmaceuticals (CLCD) and Lannett Co (LCI) Critical AnalysisCoLucid Pharmaceuticals (CLCD) and Lannett Co (LCI) Critical Analysis
www.americanbankingnews.com - October 19 at 2:10 AM
Critical Contrast: Lannett Co (LCI) & The CompetitionCritical Contrast: Lannett Co (LCI) & The Competition
www.americanbankingnews.com - October 15 at 4:28 AM
 Brokerages Anticipate Lannett Co Inc (LCI) Will Announce Quarterly Sales of $153.21 Million Brokerages Anticipate Lannett Co Inc (LCI) Will Announce Quarterly Sales of $153.21 Million
www.americanbankingnews.com - October 13 at 3:04 AM
FY2018 EPS Estimates for Lannett Co Inc (LCI) Raised by Oppenheimer HoldingsFY2018 EPS Estimates for Lannett Co Inc (LCI) Raised by Oppenheimer Holdings
www.americanbankingnews.com - October 12 at 1:54 PM
Lannett Co Inc (LCI) Expected to Post Earnings of $0.52 Per ShareLannett Co Inc (LCI) Expected to Post Earnings of $0.52 Per Share
www.americanbankingnews.com - October 11 at 8:36 PM
Lannett Co Inc Expected to Earn Q1 2018 Earnings of $0.52 Per Share (LCI)Lannett Co Inc Expected to Earn Q1 2018 Earnings of $0.52 Per Share (LCI)
www.americanbankingnews.com - October 11 at 10:12 AM
Financial Contrast: Lannett Co (LCI) and Its CompetitorsFinancial Contrast: Lannett Co (LCI) and Its Competitors
www.americanbankingnews.com - October 10 at 9:06 AM
ETFs with exposure to Lannett Co., Inc. : October 9, 2017ETFs with exposure to Lannett Co., Inc. : October 9, 2017
finance.yahoo.com - October 9 at 4:25 PM
Impax Laboratories (IPXL) vs. Lannett Co (LCI) Financial SurveyImpax Laboratories (IPXL) vs. Lannett Co (LCI) Financial Survey
www.americanbankingnews.com - October 9 at 4:12 PM
Lannett Co Inc (LCI) Receives Average Rating of "Hold" from BrokeragesLannett Co Inc (LCI) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 7 at 6:50 PM
Lannett Co., Inc. :LCI-US: Earnings Analysis: Q4, 2017 By the Numbers : October 6, 2017Lannett Co., Inc. :LCI-US: Earnings Analysis: Q4, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 7 at 2:21 AM
Lannett (LCI) Shares Cross Above 200 DMALannett (LCI) Shares Cross Above 200 DMA
www.thestreet.com - October 2 at 4:57 PM
Lannett Company Inc (LCI): What Does It Mean For Your Portfolio?Lannett Company Inc (LCI): What Does It Mean For Your Portfolio?
finance.yahoo.com - October 2 at 4:57 PM
FDA OKs Lannetts generic Prevacid; shares ahead 8%FDA OKs Lannett's generic Prevacid; shares ahead 8%
seekingalpha.com - October 2 at 12:31 PM
Lannett Co., Inc. breached its 50 day moving average in a Bullish Manner : LCI-US : September 28, 2017Lannett Co., Inc. breached its 50 day moving average in a Bullish Manner : LCI-US : September 28, 2017
finance.yahoo.com - October 2 at 12:30 PM
ETFs with exposure to Lannett Co., Inc. : September 28, 2017ETFs with exposure to Lannett Co., Inc. : September 28, 2017
finance.yahoo.com - October 2 at 12:30 PM
Corporate News Blog - Lannett Gets FDA Approval for Oxycodone and Acetaminophen Tablets USPCorporate News Blog - Lannett Gets FDA Approval for Oxycodone and Acetaminophen Tablets USP
finance.yahoo.com - October 2 at 12:30 PM

Social Media

Financials

Chart

Lannett Co (NYSE LCI) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.